In Brief: Biomira Truquant BR
This article was originally published in The Gray Sheet
Executive Summary
Biomira Truquant BR: Blood test kit for detection of recurrent breast cancer will be reviewed at FDA's Immunology Devices Panel meeting scheduled for Sept. 21 in Gaithersburg, Maryland, Biomira Diagnostics says. A premarket approval application for the assay, filed in April, has been granted expedited review by the agency. The second day of the panel meeting, which was to include panel review of "an in situ hybridization assay to measure a prognostic marker in breast tumor tissues," has been canceled, according to FDA. Panel review of an assay to measure a urinary marker in order to aid in the detection of recurrence in bladder cancer patients remains on the agenda for Sept. 21...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.